Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Glaukos’s latest 10-K sprawls across hundreds of pages detailing iStent sales trends, FDA trial timelines, and delicate MIGS reimbursement risks—crucial data that can decide an ophthalmic investor’s next move. Hunting for that information in raw SEC PDFs wastes time, especially when “Glaukos insider trading Form 4 transactions” or a sudden 8-K about a clinical milestone can shift the outlook overnight.
Stock Titan’s AI tackles the complexity head-on. It delivers “Glaukos annual report 10-K simplified,” flags every “Glaukos quarterly earnings report 10-Q filing,” and explains “Glaukos 8-K material events explained” in plain English. Need Glaukos SEC filings explained simply? With real-time alerts you’ll see “Glaukos Form 4 insider transactions real-time” the moment executives buy or sell shares. Our system pairs each filing with concise financial ratios, R&D spend summaries, and segment revenue visualizations, so understanding Glaukos SEC documents with AI becomes effortless.
Use the platform to:
- Track MIGS unit growth across quarters
- Monitor executive stock transactions Form 4 before macro catalysts
- Compare R&D intensity against peer device makers
- Review proxy statement executive compensation alongside performance
Every document is searchable, exportable, and linked to expert notes—perfect for anyone asking “How do I read Glaukos earnings report filing analysis?” Stop scrolling past jargon; start seeing only the disclosures that matter.
Glaukos Corp (GKOS) insider sale by Chief Development Officer. The filing shows Tomas Navratil sold a total of 5,142 shares on 09/11/2025 under a Rule 10b5-1 trading plan adopted June 12, 2025, at weighted average prices of $87.98 and $88.61. Following these transactions the reporting person beneficially owned 75,469 shares, which include 42,589 restricted stock units that have not vested or been delivered. The filing discloses the sales were executed in multiple trades with price ranges of $87.43–$88.43 and $88.44–$88.88 and states the reporter will provide full trade-by-trade details upon request.
Glaukos Corporation (GKOS) filed a Form 144 reporting a proposed sale of 5,142 common shares, acquired through restricted stock vesting as compensation during March–July 2024. The filing lists an aggregate market value of $453,607.98 for the shares and reports 57,349,987 shares outstanding. The proposed sale date is 09/11/2025 and the broker is listed as Fidelity Brokerage Services LLC on the NYSE. The filer reports no securities sold during the past three months and attests not to possess undisclosed material information.
Wellington Management reports beneficial ownership of 3,244,404 shares of Glaukos Corporation common stock, representing approximately 5.68% of the class. The filing shows no sole voting or dispositive power; voting power is shared for about 2,833,990 shares while shared dispositive power equals the full 3,244,404 shares disclosed.
The securities are owned of record by clients of Wellington investment advisers and are reported as held in the ordinary course of business on a Schedule 13G. Multiple Wellington entities are listed as reporting persons and two classifications appear: several entities as HC (holding companies) and Wellington Management Company LLP as IA (investment adviser).
Glaukos Corporation disclosed that it will present an investor presentation attached as Exhibit 99.1 to this Current Report and that the presentation will be made available on the company’s investor website. The company states the presentation may be used in investor and stakeholder meetings and that the information in Item 7.01 and Exhibit 99.1 is not intended to be deemed filed under the Exchange Act or incorporated by reference in other filings unless explicitly stated.
The report also lists an interactive cover page data file as Exhibit 104. No financial statements, earnings data, or material transactions are included in this filing.
FAQ
What is the current stock price of Glaukos (GKOS)?
What is the market cap of Glaukos (GKOS)?
